Bruker (NASDAQ:BRKR) Price Target Raised to $80.00

Bruker (NASDAQ:BRKR) had its target price raised by investment analysts at Bank of America from $78.00 to $80.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Bank of America‘s price target would indicate a potential upside of 39.98% from the company’s current price.

Several other equities analysts have also recently issued reports on the company. Wells Fargo & Company lowered their price objective on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. TD Cowen lowered their price target on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a report on Wednesday, November 6th. Barclays dropped their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. UBS Group assumed coverage on Bruker in a research report on Tuesday. They issued a “neutral” rating and a $66.00 target price for the company. Finally, Citigroup dropped their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $75.18.

Bruker Stock Down 2.3 %

Shares of NASDAQ BRKR traded down $1.37 during trading on Friday, reaching $57.15. The company had a trading volume of 486,213 shares, compared to its average volume of 1,109,698. Bruker has a 12-month low of $48.07 and a 12-month high of $94.86. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. The business’s 50-day moving average is $59.02 and its 200 day moving average is $63.00. The stock has a market cap of $8.66 billion, a PE ratio of 27.46, a P/E/G ratio of 4.00 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same period last year, the company posted $0.74 earnings per share. As a group, equities analysts forecast that Bruker will post 2.4 earnings per share for the current fiscal year.

Insider Transactions at Bruker

In other news, CEO Frank H. Laukien bought 100,000 shares of Bruker stock in a transaction that occurred on Monday, November 18th. The stock was bought at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the acquisition, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 28.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

Hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC lifted its holdings in Bruker by 20.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company’s stock worth $63,000 after purchasing an additional 165 shares in the last quarter. First Horizon Advisors Inc. grew its stake in Bruker by 120.4% during the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 218 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in Bruker by 0.8% during the second quarter. Ameritas Investment Partners Inc. now owns 30,911 shares of the medical research company’s stock valued at $1,972,000 after acquiring an additional 235 shares in the last quarter. US Bancorp DE increased its holdings in Bruker by 2.1% in the 3rd quarter. US Bancorp DE now owns 12,700 shares of the medical research company’s stock valued at $877,000 after acquiring an additional 260 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its stake in Bruker by 7.3% in the 3rd quarter. Coldstream Capital Management Inc. now owns 4,553 shares of the medical research company’s stock worth $312,000 after purchasing an additional 308 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.